SIMPLE通过靶向EGFR溶酶体降解保护非酒精性脂肪性肝病
该研究探讨了SIMPLE在NAFLD进展中的作用及机制。体外和体内实验表明,SIMPLE敲低加重肝细胞脂质积累和炎症,肝脏特异性敲除小鼠在高脂等饮食诱导下呈现更严重的脂肪变性、葡萄糖不耐受、炎症和纤维化;机制上SIMPLE直接结合EGFR并促进其降解,SIMPLE缺失导致EGFR过度活化,而抑制EGFR可缓解脂质积累。结论提示SIMPLE通过促进EGFR降解改善NASH,可能成为治疗候选。
要点
- SIMPLE敲低加重肝细胞脂质积累和炎症
- 肝脏SIMPLE敲除小鼠饮食诱导的脂肪性肝炎更严重
- SIMPLE通过促进EGFR降解抑制NAFLD进展
核心结论
- SIMPLE通过促进EGFR降解改善NASH,是潜在的NASH治疗候选靶点。
研究设计与样本
- 研究采用体外肝细胞模型和肝脏特异性Simple敲除小鼠,结合RNA测序及机制实验。
主要发现
- 体外敲低SIMPLE显著加重代谢刺激下肝细胞脂质积累和炎症。
- 肝脏特异性敲除小鼠在高脂饮食、高脂高胆固醇饮食及MCD饮食诱导下,脂肪变性、葡萄糖不耐受、炎症和纤维化较正常饮食对照更严重。
- RNA测序显示Simple敲除小鼠在代谢应激下脂质代谢、炎症和纤维化相关信号通路及特征基因上调。
- 机制上SIMPLE直接与EGFR相互作用,SIMPLE缺失导致EGFR降解失调、磷酸化过度激活,从而加重NAFLD。
- 使用EGFR抑制剂或沉默EGFR可改善SIMPLE敲低诱导的脂质积累。
临床怎么用
- SIMPLE可能作为NASH治疗的新靶点,促进EGFR降解或抑制EGFR活性是潜在策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: NAFLD has become a tremendous burden for public health; however, there is no drug for NAFLD therapy at present. Impaired endo-lysosome-mediated protein degradation is observed in a variety of metabolic disorders, such as atherosclerosis, type 2 diabetes mellitus, and NAFLD. Small integral membrane protein of lysosome/late endosome (SIMPLE) is a regulator of endosome-to-lysosome trafficking and cell signaling, but the role that SIMPLE plays in NAFLD progression remains unknown. Here we investigated SIMPLE function in NAFLD development and sophisticated mechanism therein. APPROACH AND RESULTS: This study found that in vitro knockdown of SIMPLE significantly aggravated lipid accumulation and inflammation in hepatocytes treated with metabolic stimulation. Consistently, in vivo experiments showed that liver-specific Simple-knockout (Simple-HKO) mice exhibited more severe high-fat diet (HFD)-induced, high-fat-high-cholesterol diet (HFHC)-induced, and methionine-choline-deficient diet (MCD)-induced steatosis, glucose intolerance, inflammation, and fibrosis than those fed with normal chow (NC) diet. Meanwhile, RNA-sequencing demonstrated the up-regulated signaling pathways and signature genes involved in lipid metabolism, inflammation, and fibrosis in Simple-HKO mice compared with control mice under metabolic stress. Mechanically, we found SIMPLE directly interact with epidermal growth factor receptor (EGFR). SIMPLE deficiency results in dysregulated degradation of EGFR, subsequently hyperactivated EGFR phosphorylation, thus exaggerating NAFLD development. Moreover, we demonstrated that using EGFR inhibitor or silencing EGFR expression could ameliorate lipid accumulation induced by the knockdown of SIMPLE. CONCLUSIONS: SIMPLE ameliorated NASH by prompting EGFR degradation and can be a potential therapeutic candidate for NASH.
引用
- Song J, Liu Y, Wan J, et al. SIMPLE Is an Endosomal Regulator That Protects Against NAFLD by Targeting the Lysosomal Degradation of EGFR. Hepatology. 2021. PMID: 34320238. doi:10.1002/hep.32075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。